Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease


News provided by

Frost & Sullivan

12 Jun, 2012, 11:45 GMT

Share this article

Share toX

Share this article

Share toX

- The company's unique Vas Zeppelin catheter-based microsurgery technology platform combines the strengths of various treatment approaches while minimizing associated risks

MOUNTAIN VIEW, California, June 12, 2012 /PRNewswire/ -- Based on its recent analysis of the pulmonary disease treatment market, Frost & Sullivan recognizes Sanovas, Inc. with the 2012 North American Frost & Sullivan Award for New Product Innovation. Sanovas's pioneering Vas Zeppelin microsurgery technology platform represents a major leap forward in the tools available to diagnose and treat lung cancer and other airway obstructions.

The increasing incidence of pulmonary disease has already reached epidemic proportions. Due to the lack of effective treatment and curative solutions, the vast majority of treatment costs go toward palliative care services that provide no chance of recovery and minimal quality-of-life enhancement for patients. The lack of effective options for this highly under-served patient population underscores the need for novel and innovative approaches.

"Given the unique anatomical structure of the lungs, most existing treatment options including surgery, chemotherapy, and radiation come with major trade-offs," says Venkat Rajan, Frost & Sullivan's industry manager for advanced medical technologies. "Sanovas is developing tools that are re-imagining what is possible in a disease where major advances in care over the past decade have been nominal."

The Vas Zeppelin catheter-based microsurgery platform is a feat in medical device convergence unlike any other. Typically, a convergent medical device indicates a two-in-one drug-device combination, diagnostic-treatment tool, or imaging-intervention product of some variety. However, Sanovas has developed a platform technology that for the first time offers physicians a flexible collection of real-time imaging, access, resection, diagnostics, and drug delivery tools in one therapy enabling system.

"The Vas Zeppelin microsurgical technology platform could be the breakthrough that significantly alters the existing paradigm," opines Venkat. "Early detection and intervention could be the key to providing patients diagnosed with lung cancer a more optimistic prognosis."

Due to its optimal profile and multifaceted construct, the Vas Zeppelin platform can conceivably address pathology found in small diameter anatomy below 3 millimeters. Altogether, Sanovas has provided an all-in-one solution at a scale and at dimensions that may very well enable early intervention in small diameter anatomies that are not currently accessible. The platform combines the strength of various treatment approaches and minimizes the associated risks of venturing into the lungs.

The Vas Zeppelin platform's on-board imaging capabilities provide interventionalists with high-resolution 3D imaging to ensure proper guidance and positioning. The catheter is constructed to provide access and sequestration without obstructing natural air or fluid flow. Depending on need and treatment determination of the clinician, unique variations of the device can deliver RF or cryo therapy. The system's Transbronchial Pressure Vacuum Actuated Micro Biopsy capsule, which allows for a sizable tissue sample to be taken in a safe manner, simplifies the operation and allows for quick immune-diagnostics and personalized medicine approaches.

Further, Sanovas has equipped the device with a combination of sensors on the catheter to provide the surgeon feedback on patient biometrics to ensure the procedure is being performed safely and provide potential warnings in case of risk to the patient or the procedure. Once the catheter position is set, the device has the ability to provide targeted drug delivery of cancer therapeutics and/or immune therapy if required. Such localized drug delivery methods help isolate diseased cells in a better manner and minimize damage to healthy tissue throughout the body.

"Due to its profile and construct, the Vas Zeppelin system also has the potential to be employed or adapted for other diseases where catheters are used in treatment," notes Venkat. "In addition to other hard-to-reach tumors, Sanovas may find significant opportunities in the treatment of peripheral vascular diseases."

Overall, Sanovas's innovative technology represents a major leap forward in the tools available to address lung cancer and other airway obstructions. Its specific design nuances demonstrate the engineering team's keen understanding of the unique set of requirements and features that could greatly impact the outcomes of surgical planning and execution. For these reasons, Sanovas is recognized as the recipient of the 2012 North American Frost & Sullivan New Product Innovation Award in the pulmonary disease medical device market.

Each year, Frost & Sullivan presents this award to the company that that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Sanovas, Inc.

Sanovas, Inc., based in Sausalito, Calif., is a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases. Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. The company plans to commercialize its technology platform, which will initially address the unmet needs in lung cancer and pulmonary disease, in 2012. Privately held Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 45 multi-national patents pending and awarded.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation, including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation

Contact:

Mireya Espinoza
P: +1-210-247-3870
F: +1-210-348-1003
E: mireya.espinoza@frost.com

Modal title

Also from this source

Ubiquity Receives Frost & Sullivan's 2025 North American Transformational Innovation Leadership Award for Excellence in Customer Experience Management

Frost & Sullivan is pleased to announce that Ubiquity Global Services has been awarded the 2025 North American Transformational Innovation Leadership ...

NTT TechnoCross Receives Frost & Sullivan's 2025 Japan Company of the Year Recognition for Leadership in Privileged Access Management

NTT TechnoCross Receives Frost & Sullivan's 2025 Japan Company of the Year Recognition for Leadership in Privileged Access Management

Frost & Sullivan is pleased to announce that NTT TechnoCross Corporation has been awarded the 2025 Japan Company of the Year Recognition in the...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Equipment

Medical Equipment

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.